In vitro evaluation of various antifungal agents alone and in combination by using an automatic turbidimetric system combined with viable count determinations

A new method combining automatic turbidimetry and sequential viable count determinations was developed to evaluate the in vitro activity of various antifungal agents alone and in combination against three clinical isolates of Candida spp. (two Candida albicans and one C. tropicalis) at two inocula (10(-5) and 10(-6) CFU/ml). Specific parameters were derived from the time-kill curves: the maximal rate of killing, the lowest biomass, and the overnight biomass. Their intra-assay and between-assay reproducibilities were high, with respective standard deviations of 0.4 and 0.25 to 1.4 log CFU/ml. Amphotericin B alone showed a linear relationship between rate of killing or lowest biomass and the log of concentration from 0.03 to 4 mg/liter that was similar for the three strains tested. 5-Fluorocytosine (flucytosine) alone showed a dose-related reduction of overnight biomass for concentrations up to 8 mg/liter with no further increase at higher concentrations for one strain of C. albicans and a paradoxical decrease for one strain of C. tropicalis. Ketoconazole alone was found to be only fungistatic with no increased activity at concentrations up to 16 mg/liter. Amphotericin B plus flucytosine interacted synergistically in 46 to 60% of the combinations tested against C. tropicalis depending on the initial inoculum. Indifference was observed for the two strains of C. albicans. Amphotericin B or flucytosine plus ketoconazole was usually indifferent against the three tested strains.

[1]  J. Galgiani,et al.  Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B , 1986, Journal of clinical microbiology.

[2]  J. Reuben,et al.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. , 1985, The Journal of infectious diseases.

[3]  G. Medoff.  Antifungal action of rifampin. , 1983, Reviews of infectious diseases.

[4]  J. Ernst,et al.  Combination antifungal chemotherapy for experimental disseminated candidiasis: lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin. , 1983, Reviews of infectious diseases.

[5]  J. Graybill,et al.  Interaction of rifampin with other antifungal agents in experimental murine candidiasis. , 1983, Reviews of infectious diseases.

[6]  D. Stevens,et al.  Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. , 1983, The Journal of infectious diseases.

[7]  F. Odds.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro , 1982, Antimicrobial Agents and Chemotherapy.

[8]  A. Flohr,et al.  Candida Infections in Surgical Patients Dose Requirements and Toxicity of Amphotericin B , 1982, Annals of surgery.

[9]  J. Utz.  Chemotherapy of the systemic mycoses. , 1973, The Medical clinics of North America.

[10]  M. Viviani.  Susceptibility testing to antifungal drugs. , 1982, Annali Sclavo; rivista di microbiologia e di immunologia.

[11]  A. Bayer,et al.  Experimental intraabdominal candidiasis in rabbits: therapy with low-total-dose intravenous amphotericin B , 1981, Antimicrobial Agents and Chemotherapy.

[12]  H. van den Bossche,et al.  In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis , 1980, Antimicrobial Agents and Chemotherapy.

[13]  M S Marriott,et al.  Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals. , 1980, Journal of general microbiology.

[14]  J. Galgiani,et al.  Turbidimetric Studies of Growth Inhibition of Yeasts with Three Drugs: Inquiry into Inoculum-Dependent Susceptibility Testing, Time of Onset of Drug Effect, and Implications for Current and Newer Methods , 1978, Antimicrobial Agents and Chemotherapy.

[15]  J. Galgiani,et al.  Antimicrobial Susceptibility Testing of Yeasts: a Turbidimetric Technique Independent of Inoculum Size , 1976, Antimicrobial Agents and Chemotherapy.

[16]  J. Hamilton,et al.  Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. , 1975, The Journal of infectious diseases.

[17]  P. Lambert,et al.  The mode of action of polyene antibiotics; induced potassium leakage in Candida albicans. , 1974, Journal of general microbiology.

[18]  D. Schlessinger,et al.  Amphotericin B Potentiation of Rifampicin as an Antifungal Agent against the Yeast Phase of Histoplasma capsulatum , 1972, Science.

[19]  D. Schlessinger,et al.  Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Medoff,et al.  Synergistic Action of Amphotericin B and 5-Fluorocytosine Against Yeast-Like Organisms 1 , 1971, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[21]  S. Shadomy.  In vitro studies with 5-fluorocytosine. , 1969, Applied microbiology.

[22]  D. E. Rogers,et al.  Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy. , 1968, The American journal of medicine.